<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6614477</article-id><article-id pub-id-type="publisher-id">46291</article-id><article-id pub-id-type="doi">10.1038/s41598-019-46291-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Human Polyclonal Antibodies Prevent Lethal Zika Virus Infection in Mice</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Branche</surname><given-names>Emilie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Simon</surname><given-names>Ayo Yila</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sheets</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Kenneth</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Barker</surname><given-names>Douglas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nguyen</surname><given-names>Anh-Viet T.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sahota</surname><given-names>Harpreet</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Young</surname><given-names>Matthew Perry</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Salgado</surname><given-names>Rebecca</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mamidi</surname><given-names>Anila</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Viramontes</surname><given-names>Karla M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Carnelley</surname><given-names>Trevor</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Qiu</surname><given-names>Hongyu</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Elong Ngono</surname><given-names>Annie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Regla-Nava</surname><given-names>Jose Angel</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Susantono</surname><given-names>Mercylia Xevana</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Valls Cuevas</surname><given-names>Joan M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kennedy</surname><given-names>Kieron</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kodihalli</surname><given-names>Shantha</given-names></name><address><email>skodihalli@ebsi.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Shresta</surname><given-names>Sujan</given-names></name><address><email>sujan@lji.org</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0461 3162</institution-id><institution-id institution-id-type="GRID">grid.185006.a</institution-id><institution>La Jolla Institute for Immunology 9420 Athena Circle, </institution></institution-wrap>La Jolla, CA 92037 USA </aff><aff id="Aff2"><label>2</label>Research and Development, Emergent BioSolutions Canada Inc, 155 Innovation Drive, Winnipeg, MB R3T 5Y3 Canada </aff><aff id="Aff3"><label>3</label>Medical Affairs, Emergent BioSolutions Canada Inc, 155 Innovation Drive, Winnipeg, MB R3T 5Y3 Canada </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>7</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>8</day><month>7</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>9</volume><elocation-id>9857</elocation-id><history><date date-type="received"><day>23</day><month>12</month><year>2018</year></date><date date-type="accepted"><day>17</day><month>6</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2019</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that represents a major threat to global health. ZIKV infections in adults are generally asymptomatic or present with mild symptoms. However, recent outbreaks of ZIKV have revealed that it can cause Congenital Zika Syndrome in neonates and Guillain-Barr&#x000e9; syndrome in adults. Currently, no ZIKV-specific vaccines or antiviral treatments are available. In this study, we tested the efficacy of convalescent plasma IgG hyperimmune product (ZIKV-IG) isolated from individuals with high neutralizing anti-ZIKV titers as a therapeutic candidate against ZIKV infection using a model of ZIKV infection in <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice. ZIKV-IG successfully protected mice from lethal ZIKV challenge. In particular, ZIKV-IG treatment at 24&#x02009;hours after lethal ZIKV infection improved survival by reducing weight loss and tissue viral burden and improving clinical score. Additionally, ZIKV-IG eliminated ZIKV-induced tissue damage and inflammation in the brain and liver. These results indicate that ZIKV-IG is efficacious against ZIKV, suggesting this human polyclonal antibody is a viable candidate for further development as a treatment against human ZIKV infection.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Protein vaccines</kwd><kwd>Viral infection</kwd></kwd-group><funding-group><award-group><funding-source><institution>Emergent BioSolutions Canada Inc, Winnipeg, Canada</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2019</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Zika virus (ZIKV) is an arthropod-borne virus belonging to the family <italic>Flaviviridae</italic>, similar to dengue, West Nile, Japanese encephalitis, and yellow fever viruses<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. ZIKV was first identified in a sentinel rhesus monkey in the Zika Forest of Uganda in 1947 and was isolated from mosquitoes (<italic>Aedes africanus</italic>) in 1948<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. ZIKV is transmitted through the bite of infected female <italic>Ae. aegypti</italic> mosquitoes<sup><xref ref-type="bibr" rid="CR3">3</xref></sup> and potentially <italic>Ae. albopictus</italic> mosquitoes<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>, as well as alternative non-vector routes which have been identified, including vertical (i.e., mother-to-infant)<sup><xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref></sup>, transfusion<sup><xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref></sup>, and sexual transmission<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. From the 1950&#x02019;s to 1990&#x02019;s, serological evidence of ZIKV was reported in multiple Asian<sup><xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref></sup> and African<sup><xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref></sup> countries, but no outbreaks and only 14 cases of human ZIKV disease were described<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref></sup>. The first ZIKV outbreak was observed in 2007 on Yap Island in the Federated States of Micronesia<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>, followed by a second outbreak in French Polynesia in 2013<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. The most recent reported outbreak was on a larger scale that occurred from 2014 to 2016 in Latin America<sup><xref ref-type="bibr" rid="CR28">28</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref></sup>. Interest in this virus increased after these outbreaks in part due to the emergence of ZIKV outside its previously known geographic range, showing the potential of the virus to spread wherever the mosquito vector is present. In addition, prior to the French Polynesia outbreak, ZIKV was known to be asymptomatic or cause only mild symptoms (fever, headache, malaise, arthralgia, myalgia, maculopapular rashes, and conjunctivitis). However, since 2007, severe complications of ZIKV infection, in particular Guillain&#x02013;Barr&#x000e9; Syndrome in adults<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup> and Congenital Zika Syndrome in babies born to ZIKV-infected women<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR36">36</xref></sup> have been observed. These findings led the WHO to declare ZIKV a public health emergency of international concern in 2016 and expanded efforts for the development of vaccines and therapeutics to combat the disease.</p><p id="Par3">Antibodies (Abs) have been shown to play a critical role in the protective immune response against infectious diseases and have been used for passive immunization, in the prevention and treatment of both bacterial and viral infections, for more than a century. Immune animal sera were first used in the late 1800&#x02019;s for treatment of disease, followed by an era of immune human serum therapy for both viral and bacterial diseases. Notably, during the 1918 influenza pandemic, serum from recovered patients was used successfully to treat acutely ill patients<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. The role of convalescent serum therapy expanded to many infections beyond influenza during the first half of the 20th century with clinical benefit demonstrated for other viral diseases like measles<sup><xref ref-type="bibr" rid="CR38">38</xref></sup> and polio<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>, and for invasive bacterial pathogens, including pneumococcus, <italic>Haemophilus influenzae B</italic>, and meningococcus<sup><xref ref-type="bibr" rid="CR40">40</xref>,<xref ref-type="bibr" rid="CR41">41</xref></sup>. Passive immunization with antibody-based therapies has emerged as a promising strategy for treating emerging infectious diseases, and include both monoclonal (mAb) and polyclonal antibodies (pAb), each of which has its advantages and disadvantages. For example, mAbs can be easily manufactured in large quantities and have a greater inherent biological consistency due to their epitope specificity as compared to pAbs. However, mAbs have limitations, including development of escape mutants and high production costs. In comparison with mAbs, pAbs can have more robust activities, neutralizing several virus strains even after viral mutations<sup><xref ref-type="bibr" rid="CR42">42</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup>. Although several studies have demonstrated that mAbs can provide therapeutic protection against ZIKV in various human and mouse models<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>, only a single study to date has shown therapeutic potential of human pAbs produced from transchromosomal cows against ZIKV infection in mice. As no study has as yet assessed the efficacy of pAbs isolated from humans as a potential therapeutic against ZIKV, herein, we evaluate the therapeutic potential of a pAb preparation from human plasma containing high anti-ZIKV titers (ZIKV-IG).</p><p id="Par4">Specifically, we used the <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mouse model as a stringent challenge system to evaluate the therapeutic potential of ZIKV-IG. Prior to the recent ZIKV epidemics, only a few studies had been performed in mice and these required many serial passages of ZIKV in mice to produce consistent disease phenotypes<sup><xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR47">47</xref></sup>. Within the last three years, substantial efforts have been focused on generating new mouse models. ZIKV evades the anti-viral type I interferon (IFN) response, in part through inhibition of the STAT2 and STING pathways in human but not mouse cells<sup><xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref></sup>. This antagonism of the type I IFN receptor (Ifnar) signaling in a species-specific manner by ZIKV explains the more severe pathogenesis of ZIKV infection in mice with immature or compromised immune systems compared to adult immunocompetent mice, and why disruption of the Ifnar1 signaling increases susceptibility of mice to lethal ZIKV infection. Accordingly, wild type mice treated with blocking anti-<italic>Ifnar1</italic> mAb<sup><xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref></sup>, and mice gene-deficient for <italic>Ifnar1</italic><sup><xref ref-type="bibr" rid="CR53">53</xref>&#x02013;<xref ref-type="bibr" rid="CR58">58</xref></sup> or for both <italic>Ifnar1</italic> and type II IFN receptors<sup><xref ref-type="bibr" rid="CR59">59</xref>&#x02013;<xref ref-type="bibr" rid="CR61">61</xref></sup> have been widely used as models of ZIKV infection. We measured the effectiveness of ZIKV-IG therapy on survival, viral burden and tissue pathology in key organs, including spleen, kidneys, liver, sciatic nerves and brain, of <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice following lethal ZIKV challenge. ZIKV-IG treatment at 24 hrs post-infection increased survival by reducing viral burden and ZIKV-induced tissue damage and inflammation in several key organs. These findings demonstrated that a single dose of ZIKV-IG is efficacious against lethal Zika disease in a highly stringent mouse challenge model.</p></sec><sec id="Sec2" sec-type="results"><title>Results</title><sec id="Sec3"><title>ZIKV-IG decreases morbidity and mortality in a dose dependent manner in <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice</title><p id="Par5">To evaluate the therapeutic efficacy of ZIKV-IG against ZIKV infection, <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice were infected with ZIKV (strain FSS13025, 1.0&#x02009;&#x000d7;&#x02009;10<sup>3</sup> FFU/mouse, retro-orbital (r.o.) route) and then treated with ZIKV-IG (50, 10, 2, 0.5 and 0.1&#x02009;mg/kg, r.o. route) 24 hrs post-infection (p.i.). ZIKV-IG used for this study exhibits high neutralization activity against multiple ZIKV strains, including strain FSS13025 (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S1</xref>). Animals were observed daily for survival, body weight changes and clinical signs of disease for day 21 p.i. For the entire study, vehicle control has been used as a negative control because the outcomes for animals treated with vehicle control were not significantly different to those observed in animals treated with a na&#x000ef;ve-ZIKV-IG placebo, and significant differences were observed between 50&#x02009;mg/kg ZIKV-IG treated mice and both vehicle control (p&#x02009;=&#x02009;0.0022) and na&#x000ef;ve-ZIKV-IG (p&#x02009;=&#x02009;0.0022) treated mice (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref> and Table&#x000a0;<xref rid="MOESM1" ref-type="media">S1</xref>). A dose-dependent effect on mortality, weight changes and severity of ZIKV disease was observed in ZIKV-IG treated animals compared to those treated with vehicle control (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Specifically, mice treated with the highest dose of ZIKV-IG (50&#x02009;mg/kg) displayed a 100% survival rate, which was significantly greater than controls (0% survival, p&#x02009;=&#x02009;0.0005), and similarly high survival rate was observed in mice treated with 10&#x02009;mg/kg as compared to control mice (87.5% survival, p&#x02009;=&#x02009;0.0042). Survival rates in the lower dose groups of 25%, 0%, and 0% (2, 0.5 and 0.1&#x02009;mg/kg, respectively) were not statistically different than for control animals (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1A</xref> and Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Similar patterns were observed in analysis of median time to death, with statistically significant increases in median time to death compared to controls for the 50&#x02009;mg/kg and 10&#x02009;mg/kg dose groups (p&#x02009;=&#x02009;0.0001 and p&#x02009;=&#x02009;0.0008, respectively) but not for the lower dose groups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). As with mortality, the 50&#x02009;mg/kg dose group showed reduced morbidity compared to the control group, with significantly different weight change and clinical score outcomes over the 21-day observation period (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1B,C</xref>). The 50&#x02009;mg/kg dose group exhibited little to no weight loss and clinical signs of disease, while the 10&#x02009;mg/kg dose group showed reduced morbidity compared to controls, but only in terms of clinical score outcomes (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1C</xref>) and not in terms of body weight (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1B</xref>). In contrast, the lowest dose groups (&#x02009;&#x02264;&#x02009;2&#x02009;mg/kg) exhibited progressive deterioration of weight (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1B</xref>) and clinical score (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1C</xref>) beginning at day 6 p.i. and extending to time of death or severe disease necessitating euthanasia. These data indicate that the 50&#x02009;mg/kg dose is the most efficacious of the doses tested against ZIKV infection in this mouse model.<fig id="Fig1"><label>Figure 1</label><caption><p>ZIKV-IG treatment improves survival of ZIKV-infected mice. Groups of <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice (n&#x02009;=&#x02009;8) were infected with 1.0&#x02009;&#x000d7;&#x02009;10<sup>3</sup> FFU of ZIKV strain FSS13025 via a retro-orbital (r.o.) route. At 24 hrs p.i., mice were treated (via r.o. route) with vehicle, 50, 10, 2, 0.5 or 0.1&#x02009;mg/kg ZIKV-IG. (<bold>A</bold>) Kaplan&#x02013;Meier survival curves. (<bold>B</bold>) Mean percent weights, which are plotted for each group relative to the percent weight on day 0 (baseline). (<bold>C</bold>) Clinical scores. Error bars represent standard error of the mean.</p></caption><graphic xlink:href="41598_2019_46291_Fig1_HTML" id="d29e648"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Analysis of survival rate between vehicle control group and ZIKV-IG-treated groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4">Comparison to vehicle control</th></tr><tr><th>Treatment Group</th><th>% Survival</th><th>Fisher&#x02019;s Exact Test p-value</th><th>Bonferroni Adjusted p-value</th></tr></thead><tbody><tr><td>Vehicle control</td><td>0 (0/8)</td><td>NA</td><td>NA</td></tr><tr><td>50&#x02009;mg/kg ZIKV-IG</td><td>100 (8/8)</td><td>0.00016**</td><td>0.0005**</td></tr><tr><td>10&#x02009;mg/kg ZIKV-IG</td><td>87.5 (7/8)</td><td>0.00014**</td><td>0.0042**</td></tr><tr><td>2&#x02009;mg/kg ZIKV-IG</td><td>25 (2/8)</td><td>0.467</td><td>1.000</td></tr><tr><td>0.5&#x02009;mg/kg ZIKV-IG</td><td>0 (0/8)</td><td>NA</td><td>NA</td></tr><tr><td>0.1&#x02009;mg/kg ZIKV-IG</td><td>0 (0/8)</td><td>NA</td><td>NA</td></tr></tbody></table></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>Analysis of median time to death between vehicle control group and ZIKV-IG-treated groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="4">Comparison to vehicle control</th></tr><tr><th>Treatment Group</th><th>Median Survival (days)</th><th>Logrank Test p-value</th><th>Bonferroni Adjusted p-value</th></tr></thead><tbody><tr><td>Vehicle control</td><td>9</td><td>NA</td><td>NA</td></tr><tr><td>50&#x02009;mg/kg ZIKV-IG</td><td>Undefined</td><td>&#x0003c;0.0001***</td><td>0.0001***</td></tr><tr><td>10&#x02009;mg/kg ZIKV-IG</td><td>Undefined</td><td>&#x0003c;0.0001***</td><td>0.0008**</td></tr><tr><td>2&#x02009;mg/kg ZIKV-IG</td><td>10.5</td><td>0.126</td><td>1.000</td></tr><tr><td>0.5&#x02009;mg/kg ZIKV-IG</td><td>9</td><td>0.675</td><td>1.000</td></tr><tr><td>0.1&#x02009;mg/kg ZIKV-IG</td><td>9</td><td>0.919</td><td>1.000</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec4"><title>ZIKV-IG treatment decreases viral replication and dissemination in <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice</title><p id="Par6">To determine how ZIKV-IG treatment improves morbidity and mortality, we examined whether ZIKV-IG treatment reduces viral burden in sera and key target organs of ZIKV tropism (spleen, kidneys, liver, sciatic nerves, and brain). <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice were infected with ZIKV (strain FSS13025, 1.0&#x02009;&#x000d7;&#x02009;10<sup>3</sup> FFU/mouse, r.o. route) followed by treatment at 24 hrs p.i. with ZIKV-IG (50, 10, 2 and 0.5&#x02009;mg/kg, r.o. route). Sera and organs were harvested on days 3 and 7 p.i., and levels of viral RNA and infectious virus to BHK cells were determined by qRT-PCR and FFA, respectively. The 0.1&#x02009;mg/kg dose was not used in this experiment due to the observed similarities of mortality and morbidity between this group and the 0.5&#x02009;mg/kg group. In the serum, only 50&#x02009;mg/kg ZIKV-IG-treated mice had significant reductions in both viral RNA (&#x02212;1.1-fold, p&#x02009;=&#x02009;0.017) and infectious virus levels (&#x02212;1.8-fold, p&#x02009;=&#x02009;0.043) at day 3 p.i. relative to vehicle-treated control mice (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2A</xref> and Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). No significant reductions were noted in any animals treated with &#x02264;10&#x02009;mg/kg ZIKV-IG on day 3 p.i. or treated with any dose level on day 7 p.i. compared to controls, suggesting that by day 7 p.i. virus is cleared from circulation in all groups (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S3</xref> and Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). In the spleen, similar levels of viral RNA and BHK cell-infectious viral particles were present in all groups at day 3 p.i., but at day 7 p.i., animals treated with 50&#x02009;mg/kg ZIKV-IG had lower levels of viral RNA (&#x02212;1.3-fold, p&#x02009;=&#x02009;0.009) and BHK cell-infectious virus (&#x02212;2.3-fold, p&#x02009;=&#x02009;0.009) relative to vehicle-treated control mice (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2B</xref> and Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). Spleens of mice treated with 10&#x02009;mg/kg ZIKV-IG (&#x02212;1.3-fold, p&#x02009;=&#x02009;0.009 for viral RNA and &#x02212;1.7-fold, p&#x02009;=&#x02009;0.009 for BHK cell-infectious ZIKV) and 2&#x02009;mg/kg ZIKV-IG (&#x02212;1.1-fold, p&#x02009;=&#x02009;0.017 for viral RNA and &#x02212;1.3-fold, p&#x02009;=&#x02009;0.035 for infectious ZIKV) also contained lower levels of viral RNA and BHK cell-infectious virus than control mice at day 7 p.i. (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S3</xref> and Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). In the kidney, 50&#x02009;mg/kg ZIKV-IG treatment significantly reduced levels of viral RNA and BHK cell-infectious virus compared to controls at both day 3 p.i (&#x02212;1.5-fold, p&#x02009;=&#x02009;0.009 for viral RNA; &#x02212;2.8-fold, p&#x02009;=&#x02009;0.009 for infectious virus) and day 7 p.i. (&#x02212;1.6-fold, p&#x02009;=&#x02009;0.009 for viral RNA; &#x02212;1.5-fold, p&#x02009;=&#x02009;0.009 for infectious ZIKV) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2B</xref> and Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). Kidneys in animals treated with 10&#x02009;mg/kg ZIKV-IG also contained decreased levels of viral RNA relative to control mice at day 3 p.i. (&#x02212;1.1-fold, p&#x02009;=&#x02009;0.035) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S3</xref> and Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). In the liver, 50&#x02009;mg/kg ZIKV-IG-treated mice had similar levels of viral RNA but lower levels of BHK cell-infectious ZIKV (&#x02212;1.3-fold, p&#x02009;=&#x02009;0.009) than control mice at day 3 p.i. (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2B</xref> and Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). At day 7 p.i., the liver RNA levels were significantly elevated in mice treated with 10&#x02009;mg/kg (1.3-fold, p&#x02009;=&#x02009;0.009), 2&#x02009;mg/kg (1.5-fold, p&#x02009;=&#x02009;0.009) and 0.5&#x02009;mg/kg ZIKV-IG (1.3-fold, p&#x02009;=&#x02009;0.017) as compared to control mice (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S3</xref> and Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>); however, no difference in levels of BHK cell-infectious virus was observed between the liver from any of the ZIKV-IG treated groups and control mice at day 7 p.i. (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S3</xref> and Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). The increased viral RNA levels observed in the liver could be related to the analytical methods, as qRT-PCR detects viral RNA of both infectious and non-infectious virus particles, whereas the FFA analysis detects only BHK cell-infectious virus particles. Collectively, these results demonstrate that ZIKV-IG treatment reduces viral burden in key non-neuronal target tissues of ZIKV.<fig id="Fig2"><label>Figure 2</label><caption><p>ZIKV-IG treatment decreases viral burden in key non-neuronal target organs of ZIKV in mice. Groups of <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice (n&#x02009;=&#x02009;6) were infected with 1.0&#x02009;&#x000d7;&#x02009;10<sup>3</sup> FFU of ZIKV strain FSS13025 (via r.o. route). At 24 hrs p.i., mice were treated (r.o. route) with either vehicle (circles) or 50&#x02009;mg/kg ZIKV-IG (squares). Viral RNA and infectious viral particle levels were determined by qRT-PCR and FFA, respectively, at days 3 and 7 p.i. in the (<bold>A</bold>) serum and (<bold>B</bold>) kidney, spleen and liver. Dotted lines indicate the limit of detection. The p values were obtained using non-parametric Wilcoxon Rank-Sum tests followed by the Bonferroni correction. Study groups were compared for statistical significance for each tissue and time-point. Error bars represent the standard error of the mean.</p></caption><graphic xlink:href="41598_2019_46291_Fig2_HTML" id="d29e964"/></fig></p><p id="Par7">As the major consequences of ZIKV infection are related to infection of the nervous system, we next compared levels of viral RNA and BHK cell-infectious virus in the peripheral and central nervous system of ZIKV-IG-treated <italic>vs</italic>. control mice. At day 3 p.i., similar levels of ZIKV RNA and infectious particles were present in the sciatic nerves of control and ZIKV-IG-treated mice, but at day 7 p.i., both viral RNA (&#x02212;2.6-fold, p&#x02009;=&#x02009;0.009) and BHK cell-infectious ZIKV (&#x02212;3.2-fold, p&#x02009;=&#x02009;0.009) levels were reduced in the sciatic nerves of animals treated with 50&#x02009;mg/kg ZIKV-IG relative to control mice (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Treatment with lower doses of ZIKV-IG also decreased levels of both viral RNA (2&#x02009;mg/kg ZIKV-IG, &#x02212;1.1-fold, p&#x02009;=&#x02009;0.035) and BHK cell-infectious virus (10&#x02009;mg/kg ZIKV-IG, &#x02212;2.6-fold, p&#x02009;=&#x02009;0.009) in the sciatic nerves at day 7 p.i (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S4</xref> and Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). In the brain, 50&#x02009;mg/kg ZIKV-IG treatment significantly reduced viral RNA levels at both days 3 and 7 p.i. (day 3 p.i. &#x02212;4.1-fold, p&#x02009;=&#x02009;0.009 and day 7 p.i. &#x02212;1.8-fold, p&#x02009;=&#x02009;0.009) relative to control mice (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3A</xref> and Supplementary Tables&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). Only low levels of BHK cell-infectious ZIKV were detected at day 3 p.i. in the brains of both 50&#x02009;mg/kg ZIKV-IG and control groups. However, at day 7 p.i., control mouse brains carried high levels of BHK cell-infectious ZIKV, and the brains from 50&#x02009;mg/kg ZIKV-IG-treated mice contained reduced levels of BHK cell-infectious ZIKV relative to control mice (&#x02212;3.5-fold, p&#x02009;=&#x02009;0.009) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3B</xref> and Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). Viral RNA (&#x02212;1.3-fold, p&#x02009;=&#x02009;0.009) and BHK cell-infectious ZIKV (&#x02212;1.8-fold, p&#x02009;=&#x02009;0.009) levels were also decreased the day 7 p.i. brains of mice treated with 10&#x02009;mg/kg ZIKV-IG (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S4</xref> and Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>). These results are consistent with the sciatic nerves and brain being major target organs of ZIKV at a later time point post infection in this mouse model, and show that ZIKV-IG treatment reduces viral burden in both peripheral and central nervous tissues.<fig id="Fig3"><label>Figure 3</label><caption><p>ZIKV-IG treatment decreases viral burden in the sciatic nerve and brain of ZIKV-infected mice. Groups of <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice (n&#x02009;=&#x02009;6) were infected with 1.0&#x02009;&#x000d7;&#x02009;10<sup>3</sup> FFU of ZIKV strain FSS13025 (via r.o. route). At 24 hrs p.i., mice were treated (r.o. route) with vehicle (circle) or 50 (square) mg/kg ZIKV-IG. (<bold>A</bold>) ZIKV RNA levels, as measured by qRT-PCR and (<bold>B</bold>) infectious ZIKV levels, as determined by FFA analyses in the sciatic nerve and brain at days 3 and 7 p.i. Dotted lines indicate the limit of detection. Study groups were compared for statistical significance using Bonferroni corrected non-parametric Wilcoxon Rank-Sum tests&#x000a0;for each tissue and time-point. Mean and standard error of the mean&#x000a0;are shown.</p></caption><graphic xlink:href="41598_2019_46291_Fig3_HTML" id="d29e1020"/></fig></p><p id="Par8">To confirm the robust efficacy of 50&#x02009;mg/kg ZIKV-IG treatment against ZIKV infection in this mouse model, we next localized ZIKV in tissues by performing immunohistochemistry (IHC) for expression of ZIKV nonstructural protein 2B (NS2B), which is absent in virions and thus serves as a marker of viral replication. In the livers of control mice (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4Aa</xref>), NS2B was expressed in cells lining sinusoids that were morphologically consistent with liver sinusoidal endothelial cells and Kupffer cells (KC). In comparison, little to no NS2B immunoreactivity was seen in livers of mice treated with 50&#x02009;mg/kg ZIKV-IG (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4Ab</xref>). Quantitative image analysis by ImageDx<sup>TM</sup> software showed that median positive cell density in control mice was 7.55 cells/mm<sup>2</sup> relative to 0.13 cells/mm<sup>2</sup> in 50&#x02009;mg/kg ZIKV-IG-treated mice (p&#x02009;=&#x02009;0.006) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4B</xref>). In the brain, NS2B was expressed in cells morphologically consistent with neurons and microglia in control mice (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4Ca</xref>), whereas little to no NS2B immunoreactivity was seen in mice treated with 50&#x02009;mg/kg ZIKV-IG (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4Cb</xref>). Quantitative analysis showed the median positive cell density in control mice was 10.88 cells/mm<sup>2</sup> as compared to 0.03 cells/mm<sup>2</sup> in 50&#x02009;mg/kg ZIKV-IG-treated mice (p&#x02009;=&#x02009;0.006) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4D</xref>). Thus, 50&#x02009;mg/kg ZIKV-IG treatment is effective against ZIKV infection in this highly stringent challenge model, as assessed via three different assays (qRT-PCR, FFA, and IHC). In particular, these results show that 50&#x02009;mg/kg ZIKV-IG treatment reduces viral burden in multiple tissues of <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice at both the early (day 3) and late (day 7) time points after infection. In comparison to 50&#x02009;mg/kg ZIKV-IG, lower doses of ZIKV-IG are less effective against ZIKV infection, reducing viral burden in select tissues.<fig id="Fig4"><label>Figure 4</label><caption><p>ZIKV-IG treatment decreases ZIKV NS2B expression in the liver and brain of ZIKV-infected mice. Groups of <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice (n&#x02009;=&#x02009;8) were infected with 1.0&#x02009;&#x000d7;&#x02009;10<sup>3</sup> FFU of ZIKV strain FSS13025 (via r.o. route). At 24 hrs p.i., mice were treated (r.o. route) with vehicle or 50&#x02009;mg/kg ZIKV-IG. At day 7 p.i., tissues were harvested to detect ZIKV NS2B expression via IHC. (<bold>A</bold>) NS2B expression in the liver (rust color dots, representative examples marked by arrows) of vehicle-treated mice after counterstaining with hematoxylin in cells morphologically consistent with LSECs and KCs. (<bold>B</bold>) NS2B expression in the liver was quantified using machine grading. (<bold>C</bold>) NS2B expression (green) was detected in vehicle-treated mice after counterstaining with DAPI in cells morphologically consistent with neurons and microglia. (<bold>D</bold>) NS2B expression was quantified using machine grading. Median and interquartile range are shown.</p></caption><graphic xlink:href="41598_2019_46291_Fig4_HTML" id="d29e1092"/></fig></p></sec><sec id="Sec5"><title>ZIKV-IG treatment decreases ZIKV-induced brain pathology</title><p id="Par9">ZIKV&#x02019;s neurotropism and associated brain pathology has been extensively documented in humans and <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice. Therefore, to evaluate the extent of brain tissue pathology and other signs of injury in ZIKV-IG-treated and control mice following ZIKV infection, hematoxylin &#x00026; eosin-stained brain slide sections were examined and scored by a blinded board-certified pathologist. Scores for these sections are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. The most significant and severe lesions seen in the brains of the control group included nonsuppurative encephalitis, gliosis, nonsuppurative meningitis, neuronal necrosis, and malacia (Table 3 and&#x000a0;Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S5</xref>). In contrast, little or no pathology was observed in mice treated with 50&#x02009;mg/kg ZIKV-IG. Thus, treatment with 50&#x02009;mg/kg ZIKV-IG reduces ZIKV-induced brain pathology (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">S5</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Grading of brain histopathology.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th rowspan="2">Treatment Group</th><th colspan="8">Grading score for brain lesion per mouse (0 to +++)</th><th rowspan="2">Most frequent observed severity (average severity)</th></tr><tr><th>m1</th><th>m2</th><th>m3</th><th>m4</th><th>m5</th><th>m6</th><th>m7</th><th>m8</th></tr></thead><tbody><tr><td rowspan="2">
<bold>Nonsuppurative encephalitis</bold>
</td><td>Ctl</td><td>++</td><td>++</td><td>++</td><td>++</td><td>+++</td><td>+++</td><td>+++</td><td>N/A</td><td>++ (2.43)</td></tr><tr><td>50&#x02009;mg/kg</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>+</td><td>+</td><td>+</td><td>0 (0.38)</td></tr><tr><td rowspan="2">
<bold>Gliosis</bold>
</td><td>Ctl</td><td>+</td><td>++</td><td>++</td><td>++</td><td>++</td><td>++</td><td>+++</td><td>N/A</td><td>++ (2.00)</td></tr><tr><td>50&#x02009;mg/kg</td><td>0</td><td>0</td><td>0</td><td>0</td><td>+</td><td>+</td><td>+</td><td>+</td><td>0/+ (0.50)</td></tr><tr><td rowspan="2">
<bold>Nonsuppurative&#x000a0;meningitis</bold>
</td><td>Ctl</td><td>+</td><td>++</td><td>++</td><td>++</td><td>++</td><td>++</td><td>++</td><td>N/A</td><td>++ (1.86)</td></tr><tr><td>50&#x02009;mg/kg</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>+</td><td>0 (0.13)</td></tr><tr><td rowspan="2">
<bold>Neural&#x000a0;necrosis</bold>
</td><td>Ctl</td><td>+</td><td>+</td><td>+</td><td>+</td><td>++</td><td>++</td><td>++</td><td>N/A</td><td>+ (1.43)</td></tr><tr><td>50&#x02009;mg/kg</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>+</td><td>+</td><td>+</td><td>0 (0.38)</td></tr><tr><td rowspan="2">
<bold>Malacia</bold>
</td><td>Ctl</td><td>0</td><td>0</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>N/A</td><td>+ (0.71)</td></tr><tr><td>50&#x02009;mg/kg</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>+</td><td>0 (0.13)</td></tr><tr><td rowspan="2">
<bold>Hemorrhage</bold>
</td><td>Ctl</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>+</td><td>+</td><td>N/A</td><td>0 (0)</td></tr><tr><td>50&#x02009;mg/kg</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0 (0)</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec6" sec-type="discussion"><title>Discussion</title><p id="Par10">In this study, we evaluated the therapeutic potential of human anti-ZIKV pAb (ZIKV-IG) against lethal ZIKV infection in a highly stringent mouse model. ZIKV-IG treatment was effective in protecting mice against ZIKV-induced mortality and morbidity by decreasing viral replication and dissemination into key target organs and ZIKV-induced pathology in the brain. These findings support further development of ZIKV-IG as a candidate for prophylaxis or treatment of Zika disease.</p><p id="Par11">A variety of Abs, including mAbs isolated from ZIKV-immune individuals<sup><xref ref-type="bibr" rid="CR62">62</xref>&#x02013;<xref ref-type="bibr" rid="CR64">64</xref></sup> and human polyclonal antibody produced in transchromosomal bovines<sup><xref ref-type="bibr" rid="CR65">65</xref></sup> were shown to have therapeutic potential against ZIKV infection in mice. Similarly, transfer of convalescent sera from a human to pregnant mice prevented ZIKV infection and associated fetal birth defects<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>, and convalescent human plasma or sera obtained from ZIKV-infected individuals were able to neutralize both African and Asian ZIKV strains <italic>in vitro</italic><sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. Here, we report that a single administration of 50&#x02009;mg/kg human polyclonal Ab (ZIKV-IG) given at 24 hrs post-infection in <italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mouse model of lethal ZIKV infection prevented both severe disease development and mortality. In addition, ZIKV-IG reduced ZIKV burden and ZIKV-induced tissue damage in target organs, confirming therapeutic potential against ZIKV infection. Recent outbreaks of several emerging and re-emerging viral diseases for which no approved treatment or vaccine exists have rekindled interest in the development of plasma-derived immunoglobulin therapeutic products. In our current study, we used human polyclonal IgG antibodies purified from convalescent donor plasma containing high titers of anti-ZIKV Abs. Plasma collection was based on criteria set by FDA and Emergent&#x02019;s standards for virus screening and donor qualification. The immunoglobulin fraction was purified using a validated hyperimmune platform manufacturing process<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>.</p><p id="Par12">Although, ZIKV strains have been phylogenetically characterized into African and Asian/American lineages, the virus has very little genome variability and is classified as a single serotype<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. This premise is supported by the report that primary infection with ZIKV African strain in macaques protected the animals from secondary heterologous re-challenge with ZIKV Asian strain<sup><xref ref-type="bibr" rid="CR69">69</xref></sup>. Thus, an effective ZIKV therapeutic candidate could potentially neutralize infection with any of the ZIKV virus lineages. Our <italic>in vitro</italic> potency based on anti-ZIKV neutralization titer and <italic>in vivo</italic> mouse results provide evidence that ZIKV-IG can effectively neutralize ZIKV infection.</p><p id="Par13">Development of Ab products intended for use as a therapy against ZIKV infection should consider the risk of antibody dependent enhancement (ADE) of infection, which has previously been described for dengue virus (DENV), another member of the family <italic>Flaviviridae</italic><sup><xref ref-type="bibr" rid="CR70">70</xref>&#x02013;<xref ref-type="bibr" rid="CR75">75</xref></sup>. During the ADE process, pre-existing non- or sub-neutralizing Abs that recognize DENV enhance subsequent DENV infection and pathogenesis<sup><xref ref-type="bibr" rid="CR76">76</xref>&#x02013;<xref ref-type="bibr" rid="CR78">78</xref></sup>. ZIKV is antigenically and genetically similar to DENV with ~56% genome sequence homology<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>, with <italic>in vitro</italic> and <italic>in vivo</italic> mouse studies demonstrating that Ab response to DENV and ZIKV can cross-react and cross-enhance infection and pathogenesis of each virus<sup><xref ref-type="bibr" rid="CR79">79</xref>&#x02013;<xref ref-type="bibr" rid="CR83">83</xref></sup>. Although recent macaque and mouse studies have provided further support for pre-existing ZIKV Ab-mediated enhancement of subsequent DENV infection and disease severity<sup><xref ref-type="bibr" rid="CR84">84</xref>&#x02013;<xref ref-type="bibr" rid="CR86">86</xref></sup>, passive transfer of vaccine-induced Abs before ZIKV challenge did not result in ZIKV infection enhancement or disease in non-pregnant mice and monkeys<sup><xref ref-type="bibr" rid="CR87">87</xref>,<xref ref-type="bibr" rid="CR88">88</xref></sup>. Consistent with these studies<sup><xref ref-type="bibr" rid="CR84">84</xref>&#x02013;<xref ref-type="bibr" rid="CR88">88</xref></sup>, treatment with various sub-protective doses of ZIKV-IG showed no evidence for ADE of ZIKV infection in our mouse model as suggested by both survival and viral RNA results. No increase in mortality or viral burden were observed even using low ZIKV-IG concentrations which are potentially sub-neutralizing. However, viral load data obtained through focus forming assays using BHK cells may not be appropriate for drawing conclusions around the presence or absence of ADE as BHK cells lack expression of Fc&#x003b3; receptors that support the ADE mode of infection.</p><p id="Par14">Whether ADE is clinically relevant to human Zika disease is currently unknown, and thus, the possibility of ZIKV-IG-mediated ADE for Zika clinical disease remains a theoretical question for the development of Ab therapies against ZIKV. Further studies should be performed to assess whether ZIKV-IG has the potential to enhance DENV infection when given under pre-exposure setting.</p><p id="Par15">In summary, we report that a single administration of 50&#x02009;mg/kg of ZIKV-IG 24 hrs after infection protected mice against lethal ZIKV infection. Non-protective doses of ZIKV-IG did not induce ADE of ZIKV infection. These results provide the evidence that, at appropriate doses, ZIKV-IG treatment could be effective at preventing the deleterious effects of ZIKV in humans. Therefore, further testing in relevant pregnancy models to determine the impact of treatment on maternal and fetal infection is warranted.</p></sec><sec id="Sec7" sec-type="materials|methods"><title>Material and Methods</title><p id="Par16">Key reagents, Abs, primers, and probes used in this study are outlined in Supplementary Table&#x000a0;<xref rid="MOESM1" ref-type="media">S3</xref>.</p><sec id="Sec8"><title>Virus</title><p id="Par17">ZIKV strains MR766, FSS13025, and PRVABC59 were obtained from the World Reference Center for Emerging Viruses and Arboviruses (WRCEVA). FSS13025 is an Asian lineage strain isolated in 2010 from a pediatric case<sup><xref ref-type="bibr" rid="CR89">89</xref></sup>. PRVABC59 is an Asian lineage strain isolated in 2015 from the blood of a human in Puerto Rico<sup><xref ref-type="bibr" rid="CR90">90</xref></sup>. MR766 is an African lineage strain isolated in 1947 from a sentinel rhesus monkey (766) in Uganda<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. Viruses were cultured using C6/36 <italic>Aedes albopictus</italic> mosquito cells, as described previously<sup><xref ref-type="bibr" rid="CR91">91</xref>,<xref ref-type="bibr" rid="CR92">92</xref></sup>. Virus was titrated using a baby hamster kidney (BHK)-21 cell-based focus-forming assay (FFA) as described previously<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>.</p></sec><sec id="Sec9"><title>Antibody neutralization assays</title><p id="Par18">Na&#x000ef;ve-ZIKV-IG and ZIKV-IG were initially diluted to 0.1&#x02009;mg/mL and then serially diluted 1:3 for 11 dilutions in RPMI 1640 medium supplemented with 1% Hepes and 1% penicillin/streptomycin. Antibody dilutions were incubated at 37&#x02009;&#x000b0;C with 5% CO<sub>2</sub> for 1&#x02009;hr with either 1&#x02009;&#x000d7;&#x02009;10<sup>5</sup> FFU of ZIKV strain FSS13025, 2&#x02009;&#x000d7;&#x02009;10<sup>4</sup> FFU of ZIKV strain MR766, or 1&#x02009;&#x000d7;&#x02009;10<sup>4</sup> FFU of ZIKV strain PRVABC59. Standard flow cytometry-based neutralization assays using U937-DC-SIGN cells were then performed as described previously<sup><xref ref-type="bibr" rid="CR58">58</xref>,<xref ref-type="bibr" rid="CR86">86</xref>,<xref ref-type="bibr" rid="CR93">93</xref></sup>.</p></sec><sec id="Sec10"><title>Mice and lethal ZIKV infection model</title><p id="Par19"><italic>Ifnar1</italic><sup>&#x02212;/&#x02212;</sup> mice (C57BL/6 mice deficient in type I interferon receptor) were originally obtained from Dr. W. Yokoyama (Washington University, St. Louis. MO) and subsequently bred under specific pathogen-free conditions at the animal facility of La Jolla Institute for Immunology. All experiments were approved by the Institutional Animal Care and Use Committee under protocol number AP028-SS1-0615/AP00001029. All experiments included age- and sex-matched mice. At 5&#x02013;6 weeks of age, mice were randomized at first by gender and secondly per weight. Mice were inoculated intravenously <italic>via</italic> the retro-orbital (r.o.) route with 1.0&#x02009;&#x000d7;&#x02009;10<sup>3</sup> FFU of ZIKV FSS13025.</p></sec><sec id="Sec11"><title>Testing of drug product and treatments</title><p id="Par20">ZIKV-IG was a purified human IgG product manufactured using plasma collected from US FDA licensed plasma centers screened for Ab reactive to ZIKV. Established processes<sup><xref ref-type="bibr" rid="CR68">68</xref></sup> were employed for manufacturing of ZIKV-IG (lot PD_740_ZKP_16_001_003_ER_v1) used in this study. This lot contained a total protein concentration of 54&#x02009;mg/mL (&#x0003e;98.9% human IgG). Potency was determined using a microneutralization assay that measured the cytopathic effect of ZIKV strain PRVABC59 on Vero E6 cells using an xCELLigence&#x000ae; real-time cell analyzer (RTCA, ACEA Biosciences Inc.). Briefly, Vero E6 cells were added to an xCELLigence 96-well electronic microtiter plate (E-plate) then pre-incubated overnight at 37&#x02009;&#x000b0;C in a humidified 5% CO<sub>2</sub> incubator. The E-plate contains electrodes in each well; adherent cells in the wells impede the electric current passing through the electrodes. An equal volume of ZIKV PRVABC59, diluted to 100 TCID<sub>50</sub>, was incubated for one hour at 37&#x02009;&#x000b0;C with serial dilutions of ZIKV-IG, then added to the E-plate. The E-plate was then incubated at 37&#x02009;&#x000b0;C in an xCELLigence unit contained in a humidified 5% CO<sub>2</sub> incubator. Cells were monitored in real-time by measuring ZIKV-induced changes in cell impedance at 30-minute intervals. Sample dilution data from the defined end point was analyzed by fitting the impedance measure (cell index) to the log dilution using a 4-parameter logistic curve fit to determine the 50% neutralizing titer (NT<sub>50</sub>). The initial potency value for ZIKV-IG product was 18,480, indicating a high degree of Zika virus neutralization.</p><p id="Par21">Na&#x000ef;ve-ZIKV-IG was manufactured using the same processes as ZIKV-IG, with the exception that the source plasma used did not contain Ab reactive to ZIKV. Mice were injected via r.o. route with 50, 10, 2.0, 0.5 or 0.1&#x02009;mg/kg ZIKV-IG (100 &#x003bc;L/mouse) at 24 hrs following lethal ZIKV infection.</p></sec><sec id="Sec12"><title>Clinical monitoring of mice and euthanasia criteria</title><p id="Par22">Following infection, mice were weighed and observed for clinical signs and scored daily. Clinical scores were based on mouse appearance, mobility, and attitude on a 7-point scale (Table&#x000a0;<xref rid="MOESM1" ref-type="media">S3</xref>). Animals losing &#x02265;20% body weight were humanely euthanized.</p></sec><sec id="Sec13"><title>Viral quantification by qRT-PCR and Focus Forming Assay</title><sec id="Sec14"><title>Sample collection</title><p id="Par23">Viral quantification was conducted by qRT-PCR and by Focus Forming Assay (FFA) on serum, spleen, kidney, liver, sciatic nerve, and brain. Sera were collected after centrifugation (15,900&#x02009;g for 15&#x02009;min at 4&#x02009;&#x000b0;C) of blood harvested by cardiac puncture into collection tubes (Sarstedt, #41.1500.005). Following mouse perfusion with PBS, tissues were harvested and stored either in tubes containing RNA Later (Invitrogen) for qRT-PCR or in pre-weighed tubes containing MEM&#x003b1; medium and steel beads (Qiagen, #69989) for FFA. Tissues were then homogenized in RTL buffer (Qiagen)&#x02009;+&#x02009;1% beta mercaptoethanol for qRT-PCR and MEM&#x003b1; medium for FFA followed by clarification (centrifugation at 2,000&#x02009;&#x000d7;&#x02009;g for 5&#x02009;min).</p></sec><sec id="Sec15"><title>Viral RNA quantification by qRT-PCR</title><p id="Par24">RNA from serum and homogenized tissues were isolated using the QIAmp Viral RNA Mini Kit (Qiagen) and the RNeasy Mini Kit (Qiagen), respectively. ZIKV RNA levels in sera and tissues were quantified by qRT-PCR. Specific primers and probes used are listed in Table&#x000a0;<xref rid="MOESM1" ref-type="media">S2</xref>. Tissue RNA levels were normalized to 18S as described for Dengue RNA<sup><xref ref-type="bibr" rid="CR91">91</xref></sup> and expressed as genome equivalent per 18S (GE/18S), while serum RNA levels were expressed as GE/mL.</p></sec><sec id="Sec16"><title>Quantification of infectious ZIKV by FFA</title><p id="Par25">FFA procedures were performed as previously described<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. Tissue samples were homogenized and clarified by centrifugation. Tissue supernatants and sera were diluted serially before infection on BHK cells. BHK cells used in this assay do not express Fc&#x003b3; receptors. Cells were plated (2.0&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/well in a 24-well plate) and incubated overnight at 37&#x02009;&#x000b0;C, 5% CO<sub>2</sub>. Confluent monolayers were inoculated with undiluted or 10-fold serially diluted sera or clarified tissue supernatant, and were incubated for 1&#x02009;hr at 37&#x02009;&#x000b0;C. After incubation, the inoculum was removed, and each cell monolayer was overlaid with CMC-media and incubated at 37&#x02009;&#x000b0;C, 5% CO<sub>2</sub> for 1.5&#x02013;2 days. Cells were then fixed, permeabilized, and incubated with pan <italic>Flavivirus</italic> anti-envelope (E) Ab clone 4G2 (BioXCell), followed by incubation with horseradish peroxidase-conjugated goat anti-mouse IgG secondary antibody (Jackson ImmunoResearch) and staining with True-Blue peroxidase substrate (Sera Care). Foci were counted, virus levels in the serum were expressed as Focus Forming Units (FFU) per mL, and for most tissues as FFU/g. As it was not technically feasible to weigh sciatic nerves, viral levels in these tissues were expressed as FFU/tissue.</p></sec></sec><sec id="Sec17"><title>Histopathology</title><p id="Par26">At the time of necropsy, liver and brain were collected in 10% zinc formalin (BBC Biochemical) for histopathologic evaluation. Tissues were fixed for 48 hrs at room temperature. Brains were cut transversely at points corresponding to Bregma +2&#x02009;mm and Bregma &#x02212;3 mm of Mouse Brain Atlas celloidin case #170 (<ext-link ext-link-type="uri" xlink:href="http://www.mbl.org">http://www.mbl.org</ext-link>), resulting in 3 brain sections (rostral, middle, and caudate). Tissues were processed routinely for paraffinization and cut at 4 &#x003bc;m thickness for H&#x00026;E staining. Slides were blinded before review with an Olympus BX40 brightfield microscope at 2-60X magnification. Lesions were graded on a 4-point scale (0 to +++). All categories of lesions were tabulated (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec18"><title>Enzyme immunohistochemistry</title><p id="Par27">Paraffinized liver was cut onto slides (4 &#x003bc;m) and routinely deparaffinized. Slides were microwaved (GE, Model#: JES1142WD04) on high setting in Antigen Unmasking Solution (Vector Laboratories) and cooled at room temperature. Endogenous enzyme activity was blocked with BLOXALL (Vector Laboratories) and nonspecific protein binding was blocked with 10% Normal Goat Serum (Thermo Fisher). Slides were incubated with anti-ZIKV NS2B Ab (Genetex) at 4&#x02009;&#x000b0;C for 14 hrs. Slides were incubated with ImmPRESS HRP (Vector Laboratories) secondary Ab followed by incubation with ImmPACT NovaRED (Vector Laboratories) substrate. Slides were counterstained with Modified Mayer&#x02019;s Hematoxylin (Thermo Fisher) and routinely processed for mounting. Positive, negative, and rabbit IgG (Vector Laboratories) controls were included with each batch. Morphology of immuno-reactive cells were confirmed by a board-certified pathologist, and immunoreactivity was quantified by ImageDx<sup>TM</sup> (Reveal Biosciences).</p></sec><sec id="Sec19"><title>Immunofluorescence</title><p id="Par28">At the time of necropsy, brains were collected in 4% paraformaldehyde (Alfa Aesar) at 4&#x02009;&#x000b0;C and allowed to fix for 24 hrs. Tissues were then cryoprotected by serial immersion in 15% sucrose (Affymetrix) followed by 20% sucrose until the brains floated. Brains were cut transversely at points corresponding to Bregma +2&#x02009;mm and Bregma &#x02212;3 mm of Mouse Brain Atlas celloidin case #170 (<ext-link ext-link-type="uri" xlink:href="http://www.mbl.org">http:/www.mbl.org</ext-link>). Tissues were transferred to cryomolds, embedded in OCT (Electron Microscopy Services), and frozen on dry ice followed by &#x02212;80&#x02009;&#x000b0;C freezer. Tissues were cut at 10&#x02009;&#x003bc;m thickness for immunofluorescence. Slides were microwaved (GE, Model#: JES1142WD04) on high setting in Antigen Unmasking Solution (Vector Laboratories) and cooled at room temperature. Slides were incubated in Tris-Urea buffer and permeabilized with 0.1% Triton X-100 (Acros Organics). Nonspecific protein binding was blocked with 10% Horse Serum (Thermo Fisher). Slides were incubated with anti-ZIKV NS2B Ab (Genetex) at 4&#x02009;&#x000b0;C for 14 hrs, followed by incubation with anti-rabbit AlexaFluor 488 (Invitrogen) secondary Ab and DAPI (Invitrogen) counterstain. Cover slips were mounted with Prolong Gold (Invitrogen). Positive, negative, and rabbit IgG (Vector Laboratories) controls were included with each batch. Morphology of cells in the brains was confirmed by a board-certified pathologist. Brain immunoreactivity was quantified by ImageDx<sup>TM</sup> (Reveal Biosciences).</p></sec><sec id="Sec20"><title>Statistical analyses</title><p id="Par29">Statistical analysis was performed using SAS version 9.3 statistical software (SAS). Survival rates and median time to death (MTD) were estimated using the Kaplan-Meier method. Data were analyzed either with Fisher&#x02019;s exact test (survival), Log-rank test (MTD) or exact Wilcoxon rank-sum test (viral RNA and infectious virus). All these tests were followed by a Bonferroni correction. Immunohistochemistry and immunofluorescence data for both brain and liver were analyzed with Kruskal-Wallis rank-sum test with Dwass, Steel, Critchlow-Fligner correction for multiple comparisons. Results were considered significant when p&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary information</title><sec id="Sec21"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2019_46291_MOESM1_ESM.pdf"><caption><p>Supplementary file</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note:</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p><bold>Supplementary information</bold> accompanies this paper at 10.1038/s41598-019-46291-9.</p></sec><ack><title>Acknowledgements</title><p>This research was supported by Emergent BioSolutions Canada Inc, Winnipeg, Canada. The animal studies described herein were conducted in accordance with the approval of the Institutional Animal Care and Use Committee of La Jolla Institute for Immunology (Protocol # AP028-SS1-0615/AP00001029).</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>E.B., A.Y.S., S.K. and S.S. conceived the project. E.B., A.Y.S. and S.K. designed experiments. E.B., N.S., K.K., A.T.N., M.P.Y., R.S., K.M.V., A.M., A.E.N., J.A.R.N., M.X.S. and J.V.C. performed experiments. E.B., A.T.N., M.P.Y., A.M., K.V., A.Y.S. and H.Q. performed quality control data screening. E.B. and A.T.N. performed the data analysis. T.C. and K.K. led the development and execution of ZIKV-IG characterization assays. H.S. performed the statistical analyses. E.B., A.Y.S. and K.K. wrote the manuscript. H.Q., D.B., S.K. and S.S. edited the manuscript.</p></notes><notes notes-type="COI-statement"><title>Competing Interests</title><p id="Par30">The study has been funded by Emergent BioSolutions Canada Inc, Winnipeg, Canada. AYE, DB, HQ, TC, HS and SK are employees of Emergent BioSolutions. EB, NS, KK, ATN, MPY, RS, KMV, AM, AEN, JARN, MXS and JVC and SS are employees of La Jolla Institute for Immunology who received funding to perform the work described.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuno</surname><given-names>G</given-names></name><name><surname>Chang</surname><given-names>GJ</given-names></name><name><surname>Tsuchiya</surname><given-names>KR</given-names></name><name><surname>Karabatsos</surname><given-names>N</given-names></name><name><surname>Cropp</surname><given-names>CB</given-names></name></person-group><article-title>Phylogeny of the genus Flavivirus</article-title><source>J Virol</source><year>1998</year><volume>72</volume><fpage>73</fpage><lpage>83</lpage><?supplied-pmid 9420202?><pub-id pub-id-type="pmid">9420202</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dick</surname><given-names>GW</given-names></name><name><surname>Kitchen</surname><given-names>SF</given-names></name><name><surname>Haddow</surname><given-names>AJ</given-names></name></person-group><article-title>Zika virus. I. Isolations and serological specificity</article-title><source>Trans R Soc Trop Med Hyg</source><year>1952</year><volume>46</volume><fpage>509</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(52)90042-4</pub-id><pub-id pub-id-type="pmid">12995440</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marchette</surname><given-names>NJ</given-names></name><name><surname>Garcia</surname><given-names>R</given-names></name><name><surname>Rudnick</surname><given-names>A</given-names></name></person-group><article-title>Isolation of Zika virus from Aedes aegypti mosquitoes in Malaysia</article-title><source>Am J Trop Med Hyg</source><year>1969</year><volume>18</volume><fpage>411</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1969.18.411</pub-id><pub-id pub-id-type="pmid">4976739</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grard</surname><given-names>G</given-names></name><etal/></person-group><article-title>Zika virus in Gabon (Central Africa)&#x02013;2007: a new threat from Aedes albopictus?</article-title><source>PLoS Negl Trop Dis</source><year>2014</year><volume>8</volume><fpage>e2681</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0002681</pub-id><?supplied-pmid 24516683?><pub-id pub-id-type="pmid">24516683</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Besnard, M., Lastere, S., Teissier, A., Cao-Lormeau, V. &#x00026; Musso, D. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. <italic>Euro Surveill</italic><bold>19</bold> (2014).</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvet</surname><given-names>G</given-names></name><etal/></person-group><article-title>Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study</article-title><source>Lancet Infect Dis</source><year>2016</year><volume>16</volume><fpage>653</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(16)00095-5</pub-id><?supplied-pmid 26897108?><pub-id pub-id-type="pmid">26897108</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mlakar</surname><given-names>J</given-names></name><etal/></person-group><article-title>Zika Virus Associated with Microcephaly</article-title><source>N Engl J Med</source><year>2016</year><volume>374</volume><fpage>951</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1600651</pub-id><?supplied-pmid 26862926?><pub-id pub-id-type="pmid">26862926</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>SA</given-names></name><name><surname>Jamieson</surname><given-names>DJ</given-names></name><name><surname>Honein</surname><given-names>MA</given-names></name><name><surname>Petersen</surname><given-names>LR</given-names></name></person-group><article-title>Zika Virus and Birth Defects&#x02013;Reviewing the Evidence for Causality</article-title><source>N Engl J Med</source><year>2016</year><volume>374</volume><fpage>1981</fpage><lpage>1987</lpage><pub-id pub-id-type="doi">10.1056/NEJMsr1604338</pub-id><?supplied-pmid 27074377?><pub-id pub-id-type="pmid">27074377</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barjas-Castro</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Probable transfusion-transmitted Zika virus in Brazil</article-title><source>Transfusion</source><year>2016</year><volume>56</volume><fpage>1684</fpage><lpage>1688</lpage><pub-id pub-id-type="doi">10.1111/trf.13681</pub-id><?supplied-pmid 27329551?><pub-id pub-id-type="pmid">27329551</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motta</surname><given-names>IJ</given-names></name><etal/></person-group><article-title>Evidence for Transmission of Zika Virus by Platelet Transfusion</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>1101</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1607262</pub-id><?supplied-pmid 27532622?><pub-id pub-id-type="pmid">27532622</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musso</surname><given-names>D</given-names></name><name><surname>Nhan</surname><given-names>T</given-names></name><name><surname>Robin</surname><given-names>E</given-names></name><name><surname>Roche</surname><given-names>C</given-names></name><name><surname>Bierlaire</surname><given-names>D</given-names></name><name><surname>Zisou</surname><given-names>K</given-names></name><name><surname>Shan Yan</surname><given-names>A</given-names></name><name><surname>Cao-Lormeau</surname><given-names>V</given-names></name><name><surname>Broult</surname><given-names>J</given-names></name></person-group><article-title>Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014</article-title><source>Eurosurveillance</source><year>2014</year><volume>19</volume><issue>14</issue><fpage>20761</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES2014.19.14.20761</pub-id><pub-id pub-id-type="pmid">24739982</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mead</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Zika Virus Shedding in Semen of Symptomatic Infected Men</article-title><source>N Engl J Med</source><year>2018</year><volume>378</volume><fpage>1377</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1711038</pub-id><?supplied-pmid 29641964?><pub-id pub-id-type="pmid">29641964</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smithburn</surname><given-names>KC</given-names></name></person-group><article-title>Neutralizing antibodies against arthropod-borne viruses in the sera of long-time residents of Malaya and Borneo</article-title><source>Am J Hyg</source><year>1954</year><volume>59</volume><fpage>157</fpage><lpage>163</lpage><?supplied-pmid 13138582?><pub-id pub-id-type="pmid">13138582</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pond</surname><given-names>WL</given-names></name></person-group><article-title>Arthropod-Borne Virus Antibodies in Sera from Residents of South-East Asia</article-title><source>Trans R Soc Trop Med Hyg</source><year>1963</year><volume>57</volume><fpage>364</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(63)90100-7</pub-id><pub-id pub-id-type="pmid">14062273</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darwish</surname><given-names>MA</given-names></name><name><surname>Hoogstraal</surname><given-names>H</given-names></name><name><surname>Roberts</surname><given-names>TJ</given-names></name><name><surname>Ahmed</surname><given-names>IP</given-names></name><name><surname>Omar</surname><given-names>F</given-names></name></person-group><article-title>A sero-epidemiological survey for certain arboviruses (Togaviridae) in Pakistan</article-title><source>Trans R Soc Trop Med Hyg</source><year>1983</year><volume>77</volume><fpage>442</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(83)90106-2</pub-id><pub-id pub-id-type="pmid">6314612</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>JG</given-names></name><etal/></person-group><article-title>A survey for arboviral antibodies in sera of humans and animals in Lombok, Republic of Indonesia</article-title><source>Ann Trop Med Parasitol</source><year>1983</year><volume>77</volume><fpage>131</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1080/00034983.1983.11811687</pub-id><pub-id pub-id-type="pmid">6309104</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simpson</surname><given-names>DI</given-names></name></person-group><article-title>Zika Virus Infection in Man</article-title><source>Trans R Soc Trop Med Hyg</source><year>1964</year><volume>58</volume><fpage>335</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(64)90201-9</pub-id><pub-id pub-id-type="pmid">14175744</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jan</surname><given-names>C</given-names></name><name><surname>Languillat</surname><given-names>G</given-names></name><name><surname>Renaudet</surname><given-names>J</given-names></name><name><surname>Robin</surname><given-names>Y</given-names></name></person-group><article-title>A serological survey of arboviruses in Gabon</article-title><source>Bull Soc Pathol Exot Filiales</source><year>1978</year><volume>71</volume><fpage>140</fpage><lpage>146</lpage><?supplied-pmid 743766?><pub-id pub-id-type="pmid">743766</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adekolu-John</surname><given-names>EO</given-names></name><name><surname>Fagbami</surname><given-names>AH</given-names></name></person-group><article-title>Arthropod-borne virus antibodies in sera of residents of Kainji Lake Basin, Nigeria 1980</article-title><source>Trans R Soc Trop Med Hyg</source><year>1983</year><volume>77</volume><fpage>149</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(83)90053-6</pub-id><pub-id pub-id-type="pmid">6306872</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monlun</surname><given-names>E</given-names></name><etal/></person-group><article-title>Surveillance of the circulation of arbovirus of medical interest in the region of eastern Senegal</article-title><source>Bull Soc Pathol Exot</source><year>1993</year><volume>86</volume><fpage>21</fpage><lpage>28</lpage><?supplied-pmid 8099299?><pub-id pub-id-type="pmid">8099299</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagbami</surname><given-names>A</given-names></name></person-group><article-title>Epidemiological investigations on arbovirus infections at Igbo-Ora, Nigeria</article-title><source>Trop Geogr Med</source><year>1977</year><volume>29</volume><fpage>187</fpage><lpage>191</lpage><?supplied-pmid 906078?><pub-id pub-id-type="pmid">906078</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Arthropod-borne viral infections of man in Nigeria, 1964-1970</article-title><source>Ann Trop Med Parasitol</source><year>1975</year><volume>69</volume><fpage>49</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1080/00034983.1975.11686983</pub-id><pub-id pub-id-type="pmid">1124969</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagbami</surname><given-names>AH</given-names></name></person-group><article-title>Zika virus infections in Nigeria: virological and seroepidemiological investigations in Oyo State</article-title><source>J Hyg (Lond)</source><year>1979</year><volume>83</volume><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1017/S0022172400025997</pub-id><pub-id pub-id-type="pmid">489960</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filipe</surname><given-names>AR</given-names></name><name><surname>Martins</surname><given-names>CM</given-names></name><name><surname>Rocha</surname><given-names>H</given-names></name></person-group><article-title>Laboratory infection with Zika virus after vaccination against yellow fever</article-title><source>Arch Gesamte Virusforsch</source><year>1973</year><volume>43</volume><fpage>315</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1007/BF01556147</pub-id><pub-id pub-id-type="pmid">4799154</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>JG</given-names></name><name><surname>Ksiazek</surname><given-names>TG</given-names></name><name><surname>Suhandiman</surname></name><name><surname>Triwibowo</surname></name></person-group><article-title>Zika virus, a cause of fever in Central Java, Indonesia</article-title><source>Trans R Soc Trop Med Hyg</source><year>1981</year><volume>75</volume><fpage>389</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(81)90100-0</pub-id><pub-id pub-id-type="pmid">6275577</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Zika virus outbreak on Yap Island, Federated States of Micronesia</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>2536</fpage><lpage>2543</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0805715</pub-id><?supplied-pmid 19516034?><pub-id pub-id-type="pmid">19516034</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao-Lormeau</surname><given-names>VM</given-names></name><etal/></person-group><article-title>Zika virus, French Polynesia, South Pacific, 2013</article-title><source>Emerg Infect Dis</source><year>2014</year><volume>20</volume><fpage>1085</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.3201/eid2006.140138</pub-id><?supplied-pmid 24856001?><pub-id pub-id-type="pmid">24856001</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>LR</given-names></name><name><surname>Jamieson</surname><given-names>DJ</given-names></name><name><surname>Powers</surname><given-names>AM</given-names></name><name><surname>Honein</surname><given-names>MA</given-names></name></person-group><article-title>Zika Virus</article-title><source>N Engl J Med</source><year>2016</year><volume>374</volume><fpage>1552</fpage><lpage>1563</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1602113</pub-id><?supplied-pmid 27028561?><pub-id pub-id-type="pmid">27028561</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Spread of Zika virus in the Americas</article-title><source>Proc Natl Acad Sci USA</source><year>2017</year><volume>114</volume><fpage>E4334</fpage><lpage>E4343</lpage><pub-id pub-id-type="doi">10.1073/pnas.1620161114</pub-id><?supplied-pmid 28442561?><pub-id pub-id-type="pmid">28442561</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colon-Gonzalez</surname><given-names>FJ</given-names></name><name><surname>Peres</surname><given-names>CA</given-names></name><name><surname>Steiner Sao Bernardo</surname><given-names>C</given-names></name><name><surname>Hunter</surname><given-names>PR</given-names></name><name><surname>Lake</surname><given-names>IR</given-names></name></person-group><article-title>After the epidemic: Zika virus projections for Latin America and the Caribbean</article-title><source>PLoS Negl Trop Dis</source><year>2017</year><volume>11</volume><fpage>e0006007</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0006007</pub-id><?supplied-pmid 29091713?><pub-id pub-id-type="pmid">29091713</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brasil</surname><given-names>P</given-names></name><etal/></person-group><article-title>Guillain-Barre syndrome associated with Zika virus infection</article-title><source>Lancet</source><year>2016</year><volume>387</volume><fpage>1482</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)30058-7</pub-id><?supplied-pmid 27115821?><pub-id pub-id-type="pmid">27115821</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bautista</surname><given-names>LE</given-names></name><name><surname>Sethi</surname><given-names>AK</given-names></name></person-group><article-title>Association between Guillain-Barre syndrome and Zika virus infection</article-title><source>Lancet</source><year>2016</year><volume>387</volume><fpage>2599</fpage><lpage>2600</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)30844-3</pub-id><?supplied-pmid 27353815?><pub-id pub-id-type="pmid">27353815</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Araujo</surname><given-names>TVB</given-names></name><etal/></person-group><article-title>Association between microcephaly, Zika virus infection, and other risk factors in Brazil: final report of a case-control study</article-title><source>Lancet Infect Dis</source><year>2018</year><volume>18</volume><fpage>328</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30727-2</pub-id><?supplied-pmid 29242091?><pub-id pub-id-type="pmid">29242091</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martines</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Pathology of congenital Zika syndrome in Brazil: a case series</article-title><source>Lancet</source><year>2016</year><volume>388</volume><fpage>898</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)30883-2</pub-id><?supplied-pmid 27372395?><pub-id pub-id-type="pmid">27372395</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucey</surname><given-names>D</given-names></name><name><surname>Cummins</surname><given-names>H</given-names></name><name><surname>Sholts</surname><given-names>S</given-names></name></person-group><article-title>Congenital Zika Syndrome in 2017</article-title><source>JAMA</source><year>2017</year><volume>317</volume><fpage>1368</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.1001/jama.2017.1553</pub-id><?supplied-pmid 28384812?><pub-id pub-id-type="pmid">28384812</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meneses</surname><given-names>JDA</given-names></name><etal/></person-group><article-title>Lessons Learned at the Epicenter of Brazil&#x02019;s Congenital Zika Epidemic: Evidence From 87 Confirmed Cases</article-title><source>Clin Infect Dis</source><year>2017</year><volume>64</volume><fpage>1302</fpage><lpage>1308</lpage><pub-id pub-id-type="doi">10.1093/cid/cix166</pub-id><?supplied-pmid 28329257?><pub-id pub-id-type="pmid">28329257</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luke</surname><given-names>TC</given-names></name><name><surname>Kilbane</surname><given-names>EM</given-names></name><name><surname>Jackson</surname><given-names>JL</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name></person-group><article-title>Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?</article-title><source>Ann Intern Med</source><year>2006</year><volume>145</volume><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-145-8-200610170-00139</pub-id><pub-id pub-id-type="pmid">16940336</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janeway</surname><given-names>CA</given-names></name></person-group><article-title>Use of Concentrated Human Serum gamma-Globulin in the Prevention and Attenuation of Measles</article-title><source>Bull N Y Acad Med</source><year>1945</year><volume>21</volume><fpage>202</fpage><lpage>222</lpage><?supplied-pmid 19312433?><pub-id pub-id-type="pmid">19312433</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammon</surname><given-names>WM</given-names></name><name><surname>Coriell</surname><given-names>LL</given-names></name><name><surname>Wehrle</surname><given-names>PF</given-names></name><name><surname>Stokes</surname><given-names>J</given-names><suffix>Jr.</suffix></name></person-group><article-title>Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. IV. Final report of results based on clinical diagnoses</article-title><source>J Am Med Assoc</source><year>1953</year><volume>151</volume><fpage>1272</fpage><lpage>1285</lpage><?supplied-pmid 13034471?><pub-id pub-id-type="pmid">13034471</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>HE</given-names></name><etal/></person-group><article-title>Hemophilus influenzae meningitis treated with streptomycin</article-title><source>J Am Med Assoc</source><year>1946</year><volume>132</volume><fpage>434</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1001/jama.1946.02870430014005</pub-id><pub-id pub-id-type="pmid">20999674</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casadevall</surname><given-names>A</given-names></name><name><surname>Scharff</surname><given-names>MD</given-names></name></person-group><article-title>Serum therapy revisited: animal models of infection and development of passive antibody therapy</article-title><source>Antimicrob Agents Chemother</source><year>1994</year><volume>38</volume><fpage>1695</fpage><lpage>1702</lpage><pub-id pub-id-type="doi">10.1128/AAC.38.8.1695</pub-id><pub-id pub-id-type="pmid">7985997</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>BS</given-names></name><name><surname>Ambrosino</surname><given-names>DM</given-names></name></person-group><article-title>History of passive antibody administration for prevention and treatment of infectious diseases</article-title><source>Curr Opin HIV AIDS</source><year>2015</year><volume>10</volume><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000154</pub-id><?supplied-pmid 25760933?><pub-id pub-id-type="pmid">25760933</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sparrow</surname><given-names>E</given-names></name><name><surname>Friede</surname><given-names>M</given-names></name><name><surname>Sheikh</surname><given-names>M</given-names></name><name><surname>Torvaldsen</surname><given-names>S</given-names></name></person-group><article-title>Therapeutic antibodies for infectious diseases</article-title><source>Bull World Health Organ</source><year>2017</year><volume>95</volume><fpage>235</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.2471/BLT.16.178061</pub-id><?supplied-pmid 28250538?><pub-id pub-id-type="pmid">28250538</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Wang, Q., Yan, J. &#x00026; Gao, G. F. Monoclonal Antibodies against Zika Virus: Therapeutics and Their Implications for Vaccine Design. <italic>J Virol</italic><bold>91</bold>, 10.1128/JVI.01049-17 (2017).</mixed-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>TM</given-names></name><name><surname>Field</surname><given-names>EJ</given-names></name><name><surname>Narang</surname><given-names>HK</given-names></name></person-group><article-title>Zika virus infection of the central nervous system of mice</article-title><source>Arch Gesamte Virusforsch</source><year>1971</year><volume>35</volume><fpage>183</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1007/BF01249709</pub-id><pub-id pub-id-type="pmid">5002906</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dick</surname><given-names>GW</given-names></name></person-group><article-title>Zika virus. II. Pathogenicity and physical properties</article-title><source>Trans R Soc Trop Med Hyg</source><year>1952</year><volume>46</volume><fpage>521</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(52)90043-6</pub-id><pub-id pub-id-type="pmid">12995441</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Way</surname><given-names>JH</given-names></name><name><surname>Bowen</surname><given-names>ET</given-names></name><name><surname>Platt</surname><given-names>GS</given-names></name></person-group><article-title>Comparative studies of some African arboviruses in cell culture and in mice</article-title><source>J Gen Virol</source><year>1976</year><volume>30</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-30-1-123</pub-id><?supplied-pmid 1245842?><pub-id pub-id-type="pmid">1245842</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>A</given-names></name><etal/></person-group><article-title>Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling</article-title><source>Cell Host Microbe</source><year>2016</year><volume>19</volume><fpage>882</fpage><lpage>890</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.05.009</pub-id><?supplied-pmid 27212660?><pub-id pub-id-type="pmid">27212660</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><etal/></person-group><article-title>Zika virus inhibits type-I interferon production and downstream signaling</article-title><source>EMBO Rep</source><year>2016</year><volume>17</volume><fpage>1766</fpage><lpage>1775</lpage><pub-id pub-id-type="doi">10.15252/embr.201642627</pub-id><?supplied-pmid 27797853?><pub-id pub-id-type="pmid">27797853</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease</article-title><source>Proc Natl Acad Sci USA</source><year>2018</year><volume>115</volume><fpage>E6310</fpage><lpage>E6318</lpage><pub-id pub-id-type="doi">10.1073/pnas.1803406115</pub-id><?supplied-pmid 29915078?><pub-id pub-id-type="pmid">29915078</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govero</surname><given-names>J</given-names></name><etal/></person-group><article-title>Zika virus infection damages the testes in mice</article-title><source>Nature</source><year>2016</year><volume>540</volume><fpage>438</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1038/nature20556</pub-id><?supplied-pmid 27798603?><pub-id pub-id-type="pmid">27798603</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elong Ngono</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mapping and Role of the CD8(+) T Cell Response During Primary Zika Virus Infection in Mice</article-title><source>Cell Host Microbe</source><year>2017</year><volume>21</volume><fpage>35</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.12.010</pub-id><?supplied-pmid 28081442?><pub-id pub-id-type="pmid">28081442</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Dengue virus-reactive CD8(+) T cells mediate cross-protection against subsequent Zika virus challenge</article-title><source>Nat Commun</source><year>2017</year><volume>8</volume><fpage>1459</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-01669-z</pub-id><?supplied-pmid 29129917?><pub-id pub-id-type="pmid">29129917</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regla-Nava</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Cross-reactive Dengue virus-specific CD8(+) T cells protect against Zika virus during pregnancy</article-title><source>Nat Commun</source><year>2018</year><volume>9</volume><fpage>3042</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-05458-0</pub-id><?supplied-pmid 30072692?><pub-id pub-id-type="pmid">30072692</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazear</surname><given-names>HM</given-names></name><etal/></person-group><article-title>A Mouse Model of Zika Virus Pathogenesis</article-title><source>Cell Host Microbe</source><year>2016</year><volume>19</volume><fpage>720</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.03.010</pub-id><?supplied-pmid 27066744?><pub-id pub-id-type="pmid">27066744</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miner</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise</article-title><source>Cell</source><year>2016</year><volume>165</volume><fpage>1081</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.05.008</pub-id><?supplied-pmid 27180225?><pub-id pub-id-type="pmid">27180225</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miner</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Zika Virus Infection in Mice Causes Panuveitis with Shedding of Virus in Tears</article-title><source>Cell Rep</source><year>2016</year><volume>16</volume><fpage>3208</fpage><lpage>3218</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.08.079</pub-id><?supplied-pmid 27612415?><pub-id pub-id-type="pmid">27612415</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8(+) T cells</article-title><source>Nat Microbiol</source><year>2017</year><volume>2</volume><fpage>17036</fpage><pub-id pub-id-type="doi">10.1038/nmicrobiol.2017.36</pub-id><?supplied-pmid 28288094?><pub-id pub-id-type="pmid">28288094</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowall</surname><given-names>SD</given-names></name><etal/></person-group><article-title>A Susceptible Mouse Model for Zika Virus Infection</article-title><source>PLoS Negl Trop Dis</source><year>2016</year><volume>10</volume><fpage>e0004658</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0004658</pub-id><?supplied-pmid 27149521?><pub-id pub-id-type="pmid">27149521</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Characterization of a Novel Murine Model to Study Zika Virus</article-title><source>Am J Trop Med Hyg</source><year>2016</year><volume>94</volume><fpage>1362</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.16-0111</pub-id><?supplied-pmid 27022155?><pub-id pub-id-type="pmid">27022155</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>WW</given-names></name><etal/></person-group><article-title>A Mouse Model of Zika Virus Sexual Transmission and Vaginal Viral Replication</article-title><source>Cell Rep</source><year>2016</year><volume>17</volume><fpage>3091</fpage><lpage>3098</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.11.070</pub-id><?supplied-pmid 28009279?><pub-id pub-id-type="pmid">28009279</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus</article-title><source>Sci Transl Med</source><year>2016</year><volume>8</volume><fpage>369ra179</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aai8336</pub-id><?supplied-pmid 27974667?><pub-id pub-id-type="pmid">27974667</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sapparapu</surname><given-names>G</given-names></name><etal/></person-group><article-title>Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice</article-title><source>Nature</source><year>2016</year><volume>540</volume><fpage>443</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/nature20564</pub-id><?supplied-pmid 27819683?><pub-id pub-id-type="pmid">27819683</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><etal/></person-group><article-title>A Single Injection of Human Neutralizing Antibody Protects against Zika Virus Infection and Microcephaly in Developing Mouse Embryos</article-title><source>Cell Rep</source><year>2018</year><volume>23</volume><fpage>1424</fpage><lpage>1434</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.04.005</pub-id><?supplied-pmid 29719255?><pub-id pub-id-type="pmid">29719255</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Human polyclonal antibodies produced in transchromosomal cattle prevent lethal Zika virus infection and testicular atrophy in mice</article-title><source>Antiviral Res</source><year>2017</year><volume>146</volume><fpage>164</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2017.09.005</pub-id><?supplied-pmid 28893603?><pub-id pub-id-type="pmid">28893603</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Transfer of convalescent serum to pregnant mice prevents Zika virus infection and microcephaly in offspring</article-title><source>Cell Res</source><year>2017</year><volume>27</volume><fpage>158</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1038/cr.2016.144</pub-id><?supplied-pmid 27922617?><pub-id pub-id-type="pmid">27922617</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowd</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype</article-title><source>Cell Rep</source><year>2016</year><volume>16</volume><fpage>1485</fpage><lpage>1491</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.07.049</pub-id><?supplied-pmid 27481466?><pub-id pub-id-type="pmid">27481466</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kammanadiminti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Combination therapy with antibiotics and anthrax immune globulin intravenous (AIGIV) is potentially more effective than antibiotics alone in rabbit model of inhalational anthrax</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e106393</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0106393</pub-id><?supplied-pmid 25226075?><pub-id pub-id-type="pmid">25226075</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aliota</surname><given-names>MT</given-names></name><etal/></person-group><article-title>Heterologous Protection against Asian Zika Virus Challenge in Rhesus Macaques</article-title><source>PLoS Negl Trop Dis</source><year>2016</year><volume>10</volume><fpage>e0005168</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0005168</pub-id><?supplied-pmid 27911897?><pub-id pub-id-type="pmid">27911897</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzman</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks</article-title><source>Rev Panam Salud Publica</source><year>2002</year><volume>11</volume><fpage>223</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1590/S1020-49892002000400003</pub-id><pub-id pub-id-type="pmid">12049030</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SB</given-names></name></person-group><article-title><italic>In vivo</italic> enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody</article-title><source>J Infect Dis</source><year>1979</year><volume>140</volume><fpage>527</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1093/infdis/140.4.527</pub-id><pub-id pub-id-type="pmid">117061</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>M</given-names></name><name><surname>Webster</surname><given-names>RG</given-names></name><name><surname>Ennis</surname><given-names>FA</given-names></name></person-group><article-title>Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses</article-title><source>J Virol</source><year>1994</year><volume>68</volume><fpage>3499</fpage><lpage>3504</lpage><?supplied-pmid 8189489?><pub-id pub-id-type="pmid">8189489</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauter</surname><given-names>P</given-names></name><name><surname>Hober</surname><given-names>D</given-names></name></person-group><article-title>Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases</article-title><source>Microbes Infect</source><year>2009</year><volume>11</volume><fpage>443</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2009.01.005</pub-id><pub-id pub-id-type="pmid">19399964</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takada</surname><given-names>A</given-names></name><name><surname>Ebihara</surname><given-names>H</given-names></name><name><surname>Feldmann</surname><given-names>H</given-names></name><name><surname>Geisbert</surname><given-names>TW</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name></person-group><article-title>Epitopes required for antibody-dependent enhancement of Ebola virus infection</article-title><source>J Infect Dis</source><year>2007</year><volume>196</volume><issue>Suppl 2</issue><fpage>S347</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1086/520581</pub-id><?supplied-pmid 17940970?><pub-id pub-id-type="pmid">17940970</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willey</surname><given-names>S</given-names></name><etal/></person-group><article-title>Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection</article-title><source>Retrovirology</source><year>2011</year><volume>8</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1186/1742-4690-8-16</pub-id><?supplied-pmid 21401915?><pub-id pub-id-type="pmid">21401915</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitehead</surname><given-names>SS</given-names></name><name><surname>Blaney</surname><given-names>JE</given-names></name><name><surname>Durbin</surname><given-names>AP</given-names></name><name><surname>Murphy</surname><given-names>BR</given-names></name></person-group><article-title>Prospects for a dengue virus vaccine</article-title><source>Nat Rev Microbiol</source><year>2007</year><volume>5</volume><fpage>518</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1038/nrmicro1690</pub-id><?supplied-pmid 17558424?><pub-id pub-id-type="pmid">17558424</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>DS</given-names></name><name><surname>Nisalak</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>DE</given-names></name><name><surname>Scott</surname><given-names>RM</given-names></name></person-group><article-title>A prospective study of dengue infections in Bangkok</article-title><source>Am J Trop Med Hyg</source><year>1988</year><volume>38</volume><fpage>172</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1988.38.172</pub-id><pub-id pub-id-type="pmid">3341519</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halstead</surname><given-names>SB</given-names></name></person-group><article-title>Neutralization and antibody-dependent enhancement of dengue viruses</article-title><source>Adv Virus Res</source><year>2003</year><volume>60</volume><fpage>421</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/S0065-3527(03)60011-4</pub-id><pub-id pub-id-type="pmid">14689700</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barba-Spaeth</surname><given-names>G</given-names></name><etal/></person-group><article-title>Structural basis of potent Zika-dengue virus antibody cross-neutralization</article-title><source>Nature</source><year>2016</year><volume>536</volume><fpage>48</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1038/nature18938</pub-id><?supplied-pmid 27338953?><pub-id pub-id-type="pmid">27338953</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dejnirattisai</surname><given-names>W</given-names></name><etal/></person-group><article-title>Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus</article-title><source>Nat Immunol</source><year>2016</year><volume>17</volume><fpage>1102</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1038/ni.3515</pub-id><?supplied-pmid 27339099?><pub-id pub-id-type="pmid">27339099</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priyamvada</surname><given-names>L</given-names></name><etal/></person-group><article-title>Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus</article-title><source>Proc Natl Acad Sci USA</source><year>2016</year><volume>113</volume><fpage>7852</fpage><lpage>7857</lpage><pub-id pub-id-type="doi">10.1073/pnas.1607931113</pub-id><?supplied-pmid 27354515?><pub-id pub-id-type="pmid">27354515</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stettler</surname><given-names>K</given-names></name><etal/></person-group><article-title>Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection</article-title><source>Science</source><year>2016</year><volume>353</volume><fpage>823</fpage><lpage>826</lpage><pub-id pub-id-type="doi">10.1126/science.aaf8505</pub-id><?supplied-pmid 27417494?><pub-id pub-id-type="pmid">27417494</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardina</surname><given-names>SV</given-names></name><etal/></person-group><article-title>Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity</article-title><source>Science</source><year>2017</year><volume>356</volume><fpage>175</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1126/science.aal4365</pub-id><?supplied-pmid 28360135?><pub-id pub-id-type="pmid">28360135</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>J</given-names></name><etal/></person-group><article-title>Prior Exposure to Zika Virus Significantly Enhances Peak Dengue-2 Viremia in Rhesus Macaques</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>10498</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-10901-1</pub-id><?supplied-pmid 28874759?><pub-id pub-id-type="pmid">28874759</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>NWW</given-names></name><name><surname>Chan</surname><given-names>KWK</given-names></name><name><surname>Vasudevan</surname><given-names>SG</given-names></name></person-group><article-title>Dengue and Zika Virus Serological Cross-reactivity and their Impact on Pathogenesis in Mice</article-title><source>J Infect Dis</source><year>2018</year><pub-id pub-id-type="doi">10.1093/infdis/jiy482</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fowler</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice</article-title><source>Cell Host Microbe</source><year>2018</year><volume>24</volume><fpage>743</fpage><lpage>750 e745</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2018.09.015</pub-id><?supplied-pmid 30439343?><pub-id pub-id-type="pmid">30439343</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbink</surname><given-names>P</given-names></name><etal/></person-group><article-title>Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys</article-title><source>Science</source><year>2016</year><volume>353</volume><fpage>1129</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1126/science.aah6157</pub-id><?supplied-pmid 27492477?><pub-id pub-id-type="pmid">27492477</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larocca</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Vaccine protection against Zika virus from Brazil</article-title><source>Nature</source><year>2016</year><volume>536</volume><fpage>474</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1038/nature18952</pub-id><?supplied-pmid 27355570?><pub-id pub-id-type="pmid">27355570</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heang</surname><given-names>V</given-names></name><etal/></person-group><article-title>Zika virus infection, Cambodia, 2010</article-title><source>Emerg Infect Dis</source><year>2012</year><volume>18</volume><fpage>349</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.3201/eid1802.111224</pub-id><?supplied-pmid 22305269?><pub-id pub-id-type="pmid">22305269</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanciotti</surname><given-names>RS</given-names></name><name><surname>Lambert</surname><given-names>AJ</given-names></name><name><surname>Holodniy</surname><given-names>M</given-names></name><name><surname>Saavedra</surname><given-names>S</given-names></name><name><surname>Signor Ldel</surname><given-names>C</given-names></name></person-group><article-title>Phylogeny of Zika Virus in Western Hemisphere, 2015</article-title><source>Emerg Infect Dis</source><year>2016</year><volume>22</volume><fpage>933</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.3201/eid2205.160065</pub-id><?supplied-pmid 27088323?><pub-id pub-id-type="pmid">27088323</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prestwood</surname><given-names>TR</given-names></name><name><surname>Prigozhin</surname><given-names>DM</given-names></name><name><surname>Sharar</surname><given-names>KL</given-names></name><name><surname>Zellweger</surname><given-names>RM</given-names></name><name><surname>Shresta</surname><given-names>S</given-names></name></person-group><article-title>A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads</article-title><source>J Virol</source><year>2008</year><volume>82</volume><fpage>8411</fpage><lpage>8421</lpage><pub-id pub-id-type="doi">10.1128/JVI.00611-08</pub-id><?supplied-pmid 18562532?><pub-id pub-id-type="pmid">18562532</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prestwood</surname><given-names>TR</given-names></name><etal/></person-group><article-title>Trafficking and replication patterns reveal splenic macrophages as major targets of dengue virus in mice</article-title><source>J Virol</source><year>2012</year><volume>86</volume><fpage>12138</fpage><lpage>12147</lpage><pub-id pub-id-type="doi">10.1128/JVI.00375-12</pub-id><?supplied-pmid 22933295?><pub-id pub-id-type="pmid">22933295</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elong Ngono</surname><given-names>A</given-names></name><etal/></person-group><article-title>CD4+ T cells promote humoral immunity and viral control during Zika virus infection</article-title><source>PLoS Pathog</source><year>2019</year><volume>15</volume><fpage>e1007474</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1007474</pub-id><?supplied-pmid 30677097?><pub-id pub-id-type="pmid">30677097</pub-id></element-citation></ref></ref-list></back></article>